Cassava Sciences (NASDAQ:FLNA – Get Free Report) and Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.
Analyst Ratings
This is a breakdown of current ratings and price targets for Cassava Sciences and Shuttle Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Shuttle Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 313.22%. Given Cassava Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Shuttle Pharmaceuticals.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.75 |
| Shuttle Pharmaceuticals | N/A | N/A | -$11.72 million | ($4.77) | -0.92 |
Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Cassava Sciences and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cassava Sciences | N/A | -53.90% | -34.20% |
| Shuttle Pharmaceuticals | N/A | -408.34% | -138.15% |
Risk and Volatility
Cassava Sciences has a beta of -0.71, suggesting that its stock price is 171% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Summary
Cassava Sciences beats Shuttle Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
